Achilles Therapeutics plc Holds General Meeting

Achilles Therapeutics PLC 6-K Filing Summary
FieldDetail
CompanyAchilles Therapeutics PLC
Form Type6-K
Filed DateMar 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting

TL;DR

Achilles Therapeutics held its meeting on 3/20/25, 42.5M shares outstanding.

AI Summary

On March 20, 2025, Achilles Therapeutics plc held its General Meeting. As of that date, the company had 42,585,094 ordinary shares outstanding. The filing does not disclose the specific outcomes or resolutions passed at the meeting.

Why It Matters

This filing confirms the date of the General Meeting and the number of outstanding shares as of that date, providing basic corporate governance information.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not contain significant financial or operational news.

Key Numbers

  • 42,585,094 — Ordinary Shares Outstanding (As of the General Meeting date, March 20, 2025.)

Key Players & Entities

  • Achilles Therapeutics plc (company) — Registrant
  • March 20, 2025 (date) — Date of General Meeting and share count
  • 42,585,094 (dollar_amount) — Number of ordinary shares outstanding

FAQ

What was the purpose of the General Meeting held by Achilles Therapeutics plc on March 20, 2025?

The filing states that a General Meeting was held on March 20, 2025, but does not specify the purpose or any resolutions.

How many ordinary shares did Achilles Therapeutics plc have outstanding as of March 20, 2025?

As of March 20, 2025, Achilles Therapeutics plc had 42,585,094 ordinary shares outstanding.

Is this filing an annual report or a periodic update?

This is a Form 6-K, which is a Report of Foreign Private Issuer, typically used for periodic reporting of material information.

What is the principal executive office address for Achilles Therapeutics plc?

The principal executive offices are located at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT, United Kingdom.

Does Achilles Therapeutics plc file annual reports under Form 20-F?

Yes, the filing indicates that the registrant files annual reports under cover of Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding Achilles Therapeutics plc.

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.